Matinas Biopharma Hl (MTNB) 1.0000 $MTNB Matinas

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Matinas Biopharma Hl (MTNB) 1.0000 $MTNB

Matinas BioPharma to Present at the 12th Anti-Infectives Partnering and Deal Making Conference
GlobeNewswire - Tue Jul 07, 6:35AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) ("Matinas BioPharma" or the "Company", a clinical-stage biopharmaceutical company, today announced that it will be presenting at the 12 Anti-Infectives Partnering and Deal Making Conference being held July 9-10, 2015, in Boston, MA.

Matinas BioPharma's MAT9001 Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa(R)
GlobeNewswire - Mon Jun 15, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company, announced the presentation of data from a head-to-head study that showed MAT9001, a prescription-only omega-3 fatty acid-based composition under development for the treatment of hypertriglyceridemia, demonstrated superiority versus Vascepa (icosapent ethyl) in reducing lipids, triglycerides, apolipoproteins and PCSK9 levels.

Matinas BioPharma to Present at the BIO International Convention on June 18, 2015
GlobeNewswire - Wed Jun 10, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting at the BIO International Convention being held June 15-18, 2015, in Philadelphia, PA.

Matinas BioPharma Announces Acceptance of Late-Breaking Abstract on MAT9001 Comparative Study Results Versus Vascepa(R) for Poster Presentation at the National Lipid Association Scientific Sessions
GlobeNewswire - Thu Jun 04, 6:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting additional data from the MAT9001 head-to-head comparative pharmacokinetic and pharmacodynamic (PK/PD) study versus Vascepa (icosapent ethyl) at the National Lipid Association (NLA) Scientific Sessions being held June 11-14, 2015, in Chicago, IL.

Matinas and Amarin's Destinies are Linked as MAT9001 Outshines Vascepa
ACCESSWIRE - Wed Jun 03, 2:42PM CDT
CORAL GABLES, FL / ACCESSWIRE / June 3, 2015 / It was April 2011 and Amarin (NASDAQ: AMRN) shareholders were flying high. As data came in for the company's pivotal phase 3 trial for Vascepa, an omega-3 fatty acid drug trialed to reduce very high triglycerides in the blood, shares went from $8.75 to a high of $19.50 just over a month later. But as excitement wore off, shares had collapsed down to pre-data-release levels by December.
AZN: 66.45 (+1.90), AMRN: 2.41 (+0.02), GSK: 42.45 (+0.65)

Matinas MAT9001 Beats Vascepa In Head-To-Head Trial
Jason Napodano, CFA - at Seeking Alpha - Mon Jun 01, 1:28PM CDT

AMRN: 2.41 (+0.02)

Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)
GlobeNewswire - Mon Jun 01, 7:00AM CDT
- MAT9001 demonstrates superiority versus Vascepa on bioavailability, triglyceride reduction and other lipid endpoints -

Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015
GlobeNewswire - Thu May 28, 6:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of targeted therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the LD Micro Invitational being held June 1-3, 2015, at the Luxe Sunset Boulevard, Los Angeles, CA.

Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
GlobeNewswire - Tue May 26, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of lipid-based prescription therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the Fourth Annual SeeThru Equity Microcap Investor Conference being held May 28, 2015, at Convene Grand Central, New York, NY.

Antifungals, an Overlooked Biotech Niche With Big Potential
ACCESSWIRE - Wed May 20, 7:37AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 20, 2015 / If a global competition were held for the planet's most sadly ironic places, the hospital would place very high, if not win outright. This is not only true from before the late 19th century when the germ theory of disease became widely accepted. Before then, the hospital - a place that is designed to heal the sick - was just about the best place on Earth to contract a life-threatening infection due to unsanitary surgical procedures. This is still sadly true today as well. Hospitals are still the largest breeding grounds for deadly superbug infections due to the very sanitation procedures meant to stop them.
CDTX: 14.43 (+0.43), RTGN: 5.06 (+1.01)

Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 9.13 (+0.49), BIIB: 388.23 (-11.06), ARWR: 6.68 (+0.07), AMGN: 154.10 (+2.79), MYL: 71.22 (+0.87), BMY: 69.27 (+1.38), CNCE: 15.71 (+0.27), CELG: 118.84 (+1.97), ATNM: 2.41 (+0.18), PFS: 19.19 (+0.20), NVIV: 14.01 (-1.01), GILD: 113.74 (+0.38), FWP: 39.47 (+1.55), GWPH: 125.86 (+5.39), IBM: 166.95 (+3.10), BAX: 37.61 (+0.59), AZN: 66.45 (+1.90), TEVA: 61.38 (-0.75)

Matinas' Pipeline Is Ready To Shine
Jason Napodano, CFA - Seeking Alpha - Thu Apr 16, 2:26PM CDT
By Jason Napodano, CFA On January 30, 2015, Matinas announced the establishment of a lipid-based, anti-infective platform with the acquisition of Aquarius BioTechnologies, Inc. This was the Bioral™ technology previously owned by BioDelivery...

Matinas BioPharma Completes Private Placement of $10 Million
GlobeNewswire - Fri Apr 10, 11:20AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of infectious diseases and cardiovascular and metabolic conditions, today announced the closing of a $10 million private placement equity financing, which represents the full amount of the offering. The Company sold to accredited investors an aggregate of 20,000,000 units at a price of $0.50 per unit, with each unit consisting of one share of the Company's common stock and a five-year warrant to purchase one share of common stock at an exercise price of $0.75 per share.

Matinas BioPharma to Present at the 2nd Annual Growth Capital Expo on April 13, 2015
GlobeNewswire - Tue Apr 07, 7:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of infectious diseases and cardiovascular and metabolic conditions, today announced that its President and Chief Executive Officer, Roelof Rongen, will be presenting on Monday, April 13, 2015, at 8:30 a.m. Pacific Daylight Time, at the 2 Annual Growth Capital Expo being held April 12-14, 2015, at Caesars Palace in Las Vegas, Nevada.

Apparent Connections To A Convicted Stock Promoter: Another Chapter In The Organovo Saga
Alpha Exposure - Seeking Alpha - Wed Apr 01, 12:16PM CDT
Much has been written about Organovo (NYSEMKT: ONVO ) and its shortcomings. Richard Pearson showed that Organovo's 3D liver tissue is not unique, that competitors are more advanced than ONVO, and that the market opportunity for liver assays is...
ONVO: 3.82 (+0.26)

Matinas BioPharma Completes Enrollment in First Human Trial of MAT9001
GlobeNewswire - Mon Mar 30, 7:05AM CDT
- Study Steering Committee Recommends Early Completion of Enrollment Due to Adequate Power in Study to Demonstrate Study Endpoints -

Matinas BioPharma to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
GlobeNewswire - Thu Feb 05, 7:07AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions and the treatment of infectious diseases, announced today that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York.

Matinas Biopharma Acquires Aquarius Biotechnologies
Jason Napodano, CFA - at Seeking Alpha - Wed Feb 04, 6:09PM CST


Matinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, With Acquisition of Aquarius BioTechnologies Inc.
GlobeNewswire - Fri Jan 30, 7:25AM CST
- Novel lipid-crystal nano-particle cochleate formulation delivery platform with opportunity for broad use in anti-infectives featuring targeted delivery and multi-organ protection -

Matinas BioPharma Holdings, Inc. - Increasing Evidence That Elevated Triglycerides Cause Cardiovascular Events
ACCESSWIRE - Thu Jan 08, 12:18PM CST
New York, NY / ACCESSWIRE / January 8, 2015 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a new blog post on The Chairman's Blog, written by the Company's Co-Founder and CEO, Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 70

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 11

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 30

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 121

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 39

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Matt Hougan Shares Insights on Bitcoin's Potential Surge

Updated Category News Views 165

Understanding Bitcoin's Growth Potential Matt Hougan, the Chief Investment Officer at Bitwise, sheds light on the driving forces behind the burgeoning interest in Bitcoin. He emphasizes concerns over the decline of fiat currencies and noteworthy inflows into Bitcoin ETFs as the catalysts propelling Bitcoin's journey towards new heights. This surge towards potential record...

Continue Reading
Empowering Futures: Access Bank's Commitment to Education

Updated Category News Views 174

Support for Educational Development In recent years, The Access Bank UK Ltd has made significant strides in supporting educational initiatives aimed at transforming lives. This commitment is exemplified by the annual Polo Cup event that they host in collaboration with UNICEF and Fifth Chukker. The Access Bank Cup has become more than just a sporting affair; it is a beacon...

Continue Reading
Gary Brecka's Event Redefines Longevity's Future in L.A.

Updated Category News Views 46

Exploring Longevity: A Day Like No Other Alright, picture this: a convergence of wellness diehards, human performance buffs, and curious minds, all filing into the Peacock Theater in Los Angeles. It's August 16th and they're here for Gary Brecka LIVE. This is no run-of-the-mill wellness seminar; it's an exclusive deep dive into the world of longevity hosted by Sequel...

Continue Reading
Ultragenyx Pharmaceutical and Others Face Challenges in Ratings

Updated Category News Views 164

Stock Market Overview This morning, U.S. stock futures indicated a downward trend, with the Dow futures decreasing by about 100 points. Given the numerous fluctuations in the market recently, this drop is indicative of the challenges many companies are facing. Ultragenyx Pharmaceutical Inc Performance Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have sharply...

Continue Reading
Netflix's Future: Overcoming Slower Subscriber Growth Strategies

Updated Category News Views 185

Analyzing Netflix's Subscription Growth and Future Strategies Netflix, a leading name in streaming services, is facing a potential slowdown in subscriber additions. Analysts suggest that the streaming giant might experience its most modest subscriber growth in the past six quarters as the gains from its recent password-sharing crackdown start to wane. With this shifting...

Continue Reading